PHARMACYTE BIOTECH, INC. Payments of Ordinary Dividends, Preferred Stock and Preference Stock
PHARMACYTE BIOTECH, INC. (PMCB) reported Payments of Ordinary Dividends, Preferred Stock and Preference Stock of $22.49 million for the 12-month period ending 2025-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock · last filed 2026-07-29
- PHARMACYTE BIOTECH, INC. payments of ordinary dividends, preferred stock and preference stock for the quarter ending 2025-04-30 was $3.72M, a 76.26% decline year-over-year.
- PHARMACYTE BIOTECH, INC. payments of ordinary dividends, preferred stock and preference stock for the quarter ending 2025-01-31 was $0.00, a 100.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. payments of ordinary dividends, preferred stock and preference stock for the quarter ending 2024-10-31 was $9.34M, a 2481.25% increase year-over-year.
- PHARMACYTE BIOTECH, INC. payments of ordinary dividends, preferred stock and preference stock for the quarter ending 2024-07-31 was $9.43M.
- PHARMACYTE BIOTECH, INC. payments of ordinary dividends, preferred stock and preference stock for fiscal 2025 was $22.49M, a 39.15% increase from fiscal 2024.
- PHARMACYTE BIOTECH, INC. payments of ordinary dividends, preferred stock and preference stock for fiscal 2024 was $16.16M.
| Period end | Payments of Ordinary Dividends, Preferred Stock and Preference Stock 3 month | Payments of Ordinary Dividends, Preferred Stock and Preference Stock 6 month | Payments of Ordinary Dividends, Preferred Stock and Preference Stock 9 month | Payments of Ordinary Dividends, Preferred Stock and Preference Stock 12 month |
|---|---|---|---|---|
| 2025-04-30 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $3.72M derived: sum of 2 quarters · filed 2026-07-29 | $13.06M derived: sum of 3 quarters · filed 2026-07-29 | $22.49M 10-K · filed 2026-07-29 |
| 2025-01-31 | $0.00 10-Q · filed 2025-03-17 | $9.34M derived: sum of 2 quarters · filed 2025-03-17 | $18.77M 10-Q · filed 2025-03-17 | $34.44M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-10-31 | $9.34M 10-Q · filed 2024-12-13 | $18.77M 10-Q · filed 2024-12-13 | $34.44M derived: sum of 3 quarters · filed 2025-08-11 | $34.57M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-07-31 | $9.43M 10-Q · filed 2024-09-17 | $25.10M derived: sum of 2 quarters · filed 2025-08-11 | $25.23M derived: sum of 3 quarters · filed 2025-08-11 | $25.59M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-04-30 | $15.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | $15.80M derived: sum of 2 quarters · filed 2025-08-11 | $16.16M derived: sum of 3 quarters · filed 2025-08-11 | $16.16M 10-K · filed 2025-08-11 |
| 2024-01-31 | $129.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-18 | $491.62K derived: sum of 2 quarters · filed 2024-03-18 | $491.62K 10-Q · filed 2024-03-18 | |
| 2023-10-31 | $361.72K 10-Q · filed 2023-12-15 | $361.72K 10-Q · filed 2023-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |